B-cell receptor specific for the tumor idiotype (BCR-idiotype)

The B-cell receptor (BCR) specific for the tumor idiotype is a unique, patient-specific antigen found on the surface of malignant B cells in lymphoproliferative disorders. Each B-cell clone expresses a BCR with a unique variable region, known as the idiotype, which arises from somatic V(D)J recombination during B-cell development. Because this idiotype is exclusive to the neoplastic clone and absent from healthy B cells, it serves as a highly specific neoantigen for targeted therapy. In B-cell malignancies such as follicular lymphoma and multiple myeloma, the idiotype is utilized as a target for personalized vaccines and monoclonal antibodies. Therapeutic strategies typically involve isolating the patient's specific idiotype and using it to stimulate a systemic immune response against the tumor. While idiotype-targeted therapies have shown promise in maintaining remissions, the requirement for custom manufacturing for every patient remains a significant clinical and logistical challenge.

Other names

Tumor-specific idiotypeClonal B-cell receptorIdiotypic determinantSurface immunoglobulin idiotypeB-cell receptor idiotype

Active immunotherapy involves the administration of patient-specific idiotype proteins (often conjugated to carrier proteins like KLH) to induce a host immune response (T-cell and B-cell mediated) against the unique tumor-specific BCR. Passive immunotherapy utilizes monoclonal anti-idiotype antibodies to directly target the malignant B-cell clone, inducing apoptosis or antibody-dependent cellular cytotoxicity (ADCC).